自身炎症性疾病溶骨性骨髓炎及膜结构调控蛋白PSTPIP2的研究进展

霍庆然<sup>1; 2; 3</sup>; 董　阁<sup>1; 2; 3</sup>; 蔡志刚<sup>1; 2; 3</sup>

引用本文:	霍庆然，董　阁，蔡志刚.自身炎症性疾病溶骨性骨髓炎及膜结构调控蛋白PSTPIP2的研究进展[J].中国临床新医学,2026,19(2):166-171.

【打印本页】【下载PDF全文】【查看/发表评论】【EndNote】【RefMan】【BibTex】

←前一篇|后一篇→

过刊浏览高级检索

本文已被：浏览 10次下载 14次	码上扫一扫！
分享到：微信更多字体:加大+\|默认\|缩小-
自身炎症性疾病溶骨性骨髓炎及膜结构调控蛋白PSTPIP2的研究进展
霍庆然^1，2，3，董　阁^1，2，3，蔡志刚^1，2，3
1.天津医科大学基础医学院药理学系，天津 300070；2.血液与健康全国重点实验室，天津 300070；3.天津市炎症生物学重点实验室，天津 300070

摘要:

［摘要］　先天免疫作为机体抵御病原体入侵的第一道防线，在维持免疫系统稳态、识别并清除入侵病原体方面发挥重要作用。然而，在无菌条件下，先天免疫异常激活可能引发自身炎症性疾病。慢性-复发性-多灶性-溶骨性骨髓炎（CRMO）作为自身炎症性疾病的典型代表，在临床诊疗方面仍存在诸多亟待解决的基础理论和临床管理问题。CRMO小鼠模型Pstpip2^-/-在自身炎症性疾病和CRMO研究领域中被广泛应用，并加深针对CRMO疾病在分子细胞水平的调控机制的理解。该文总结了一般性自身炎症性疾病的临床表现特征和分类，重点探讨膜结构调控蛋白PSTPIP2在CRMO Pstpip2^-/-小鼠模型中的作用，旨在为解析溶骨性骨髓炎的发病机制及制订治疗策略提供参考。

关键词: 固有免疫自身炎症性疾病溶骨性骨髓炎膜结构调控蛋白PSTPIP2

DOI：10.3969/j.issn.1674-3806.2026.02.09

分类号:R 593

基金项目:国家自然科学基金项目（编号：82170173，82371789，U25A2050）；天津市教委科研计划项目（编号：2022KJ194）

Research progress in the autoinflammatory disease osteolytic osteomyelitis and membrane-regulating protein PSTPIP2

HUO Qingran^1,2,3, DONG Ge^1,2,3, CAI Zhigang^1,2,3

1.Department of Pharmacology, School of Basic Medical Science, Tianjin Medical University, Tianjin 300070, China; 2.State Key Laboratory of Experimental Hematology, Tianjin 300070, China; 3.Tianjin Key Laboratory of Inflammatory Biology, Tianjin 300070, China

Abstract:

［Abstract］　Innate immunity, as the first line of defense for the body against the invasion of pathogens, plays a significant role in maintaining the homeostasis of the immune system, and in recognizing and eliminating the invading pathogens. However, under aseptic conditions, the abnormal activation of innate immunity may induce autoinflammatory diseases. Chronic recurrent multifocal osteomyelitis(CRMO), as a typical representative of autoinflammatory diseases, still has many fundamental theoretical and clinical management problems that need to be urgently solved in clinical diagnosis and treatment. The Pstpip2^-/- mouse model is widely used in the research fields of autoinflammatory diseases and CRMO, which facilitates the understanding of the regulatory mechanisms of CRMO at the molecular and cellular levels. This paper summarizes the clinical manifestations and classifications of general autoinflammatory diseases, with a focus on discussing the role of membrane-regulating protein proline-serine-threonine-phosphatase-interacting protein 2(PSTPIP2) in the Pstpip2^-/- mouse model of CRMO, aiming to provide a reference for analyzing the pathogenesis of osteolytic osteomyelitis and formulating therapeutic strategies.

Key words: Innate immunity Autoinflammatory diseases Osteolytic osteomyelitis Membrane-regulating protein proline-serine-threonine-phosphatase-interacting protein 2(PSTPIP2)